Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health (The VIAB2L Project)

NCT06425081 is registered in ClinicalTrials.gov with dsm-firmenich Switzerland AG as lead sponsor.

NCT NCT06425081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06425081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Impact of Humiome B2 (Colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health (The VIAB2L Project)
Lead sponsor
dsm-firmenich Switzerland AG
Phase
Not applicable
Overall status
Completed
Start date
September 9, 2024
Completion date
January 30, 2025
Enrollment
185 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microbial colonization